Circulate Health equips longevity and wellness clinics with a turnkey therapeutic-plasma-exchange (TPE) solution—FDA-cleared hardware, patented toxin-removal protocols, and on-site apheresis nurses— enabling blood-purification services that reduce micro-plastics, senescent factors, and biological-age markers.
About the company
Circulate Health is pioneering preventive “blood maintenance” by making clinical-grade TPE accessible outside the hospital. The company delivers a complete package—machines, consumables, SOPs, and trained staff—so clinics can go live in under eight weeks and reach breakeven at only a handful of monthly treatments. Early studies show a 2.6-year reversal in biological-age clocks and meaningful reductions in environmental toxins and inflammatory proteins.
Founded by Dr. Brad Younggren and Robbie Schwietzer (alumni of 98point6, which scaled through nearly $300 M in funding), Circulate has assembled leading experts in plasmapheresis and longevity research, including Dr. Dobri Kiprov and Dr. Eric Verdin. Backing from Khosla Ventures provides the capital and network to expand rapidly across U.S. longevity and functional-medicine clinics.
Why We Invested
The rise of blood-health awareness—propelled by consumer testing services and growing concern over micro-plastics, PFAS, and age-accelerating proteins—has exposed a glaring gap: we can measure toxins, but we can’t easily remove them. Circulate Health answers this unmet need with a capital-light, turnkey plasma-exchange platform that lets existing longevity and functional-medicine clinics add a high-margin blood-purification service in weeks. Early data showing meaningful toxin reduction and a 2.6-year reversal in biological-age clocks highlight the therapy’s potential to become as routine as an annual dental cleaning.
Equally important, the company is led by proven entrepreneurs, Dr. Brad Younggren and Robbie Schwietzer, and is backed by Khosla Ventures. Their execution track record, combined with Circulate’s strong IP around toxin removal and apheresis protocols, gives us confidence that the team can turn an emerging clinical procedure into the defining standard for preventive blood maintenance.